RT Journal Article
SR Electronic
T1 COVID-19 superspreading in cities versus the countryside
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.04.20188359
DO 10.1101/2020.09.04.20188359
A1 Andreas Eilersen
A1 Kim Sneppen
YR 2020
UL http://medrxiv.org/content/early/2020/09/07/2020.09.04.20188359.abstract
AB So far, the COVID-19 pandemic has been characterised by an initial rapid rise in new cases followed by a peak and a more erratic behaviour that varies between regions. This is not easy to reproduce with traditional SIR models, which predict a more symmetric epidemic. Here, we argue that superspreaders and population heterogeneity are the core factors explaining this discrepancy. We do so through an agent-based lattice model of a disease spreading in a heterogeneous population. We predict that an epidemic driven by superspreaders will spread rapidly in cities, but not in the countryside where the sparse population limits the maximal number of secondary infections. This suggests that mitigation strategies should include restrictions on venues where people meet a large number of strangers. Furthermore, mitigating the epidemic in cities and in the countryside may require different levels of restrictions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementOur research has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under grant agreement No. [740704].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable (theoretical modelling study)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAn implementation of the model described in this article can be found on figshare under the DOI https://doi.org/10.6084/m9.figshare.12919709.v1 https://doi.org/10.6084/m9.figshare.12919709.v1